Tab Application Banner
  • Users Online: 572
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2022  |  Volume : 17  |  Issue : 2  |  Page : 136-141

Effectiveness of colchicine among patients with COVID-19 infection: A randomized, open-labeled, clinical trial


1 Department of Rheumatology, Rizgari Teaching Hospital, Kurdistan Board for Medical Specialities, Erbil, Iraq
2 Department of Medicine, Rizgary Teaching Hospital, Erbil, Iraq

Correspondence Address:
Dr. Aryan Mohamadfatih Jalal
Department of Rheumatology, Rizgari Teaching Hospital, Kurdistan Board for Medical Specialities, Erbil
Iraq
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/injr.injr_264_21

Rights and Permissions

Background and Objective: In November 2019, there were abundant cases of COVID-19 which first case was reported in Wuhan, China. Colchicine has an important role in inhibiting activation of NLRP3 inflammasome that predispose to decrease cytokine production. This study aimed to evaluate whether colchicine is effective in treatment of corona virus disease of 2019 (COVID-19) patients or not. Patients and Methods: A randomized, open-labeled, clinical trial of Colchicine for the treatment of COVID-19, allocated between May 8, and June 18, 2021. The colchicine tablet dosage was 0.5 mg twice daily for 14 days added to the standard treatment versus control group who receive standard treatment without colchicine, with the trial registration ID: NCT04867226. The study was conducted in Erbil city-Iraq with the endpoints being clinical, laboratory parameters and duration of hospitalization. Results: Eighty patients participated in the study. Fewer patients in the colchicine group had musculoskeletal symptoms (17.5%, P = 0.001) in comparison to the patients, who received control treatment. The serum ferritin level in most of patients who treated with colchicine returned to normal in contrast to the control group, whose serum ferritin level was still high (P = 0.041). Similarly, the average of C-reactive protein and D-dimer after treatment among the colchicine group participants was significantly lower than the control group, the P values were 0.011 and 0.043 consecutively. The colchicine group patients stayed for a shorter duration at the hospital (18.4 days) compared to the control group (24.24 days). P value was 0.009. In addition to that the response and cure rate were higher in the colchicine group (56%) in the comparison to control group (43.1%). Conclusion: The colchicine drug can be effective in treating patients with COVID-19 infection by improving musculoskeletal symptoms and inhibiting inflammatory biomarkers; it is also effective in reducing duration of hospitalization.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1923    
    Printed14    
    Emailed0    
    PDF Downloaded38    
    Comments [Add]    

Recommend this journal